ClinicalTrials.gg
CompletedNCT01588405Updated May 16, 2016Results posted

Remodulin® to Oral Treprostinil Transition

A Phase 2 interventional study of UT-15C SR in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 6 sites in United States. Open to participants aged 15 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-05-16.

Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
15 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
21st of 44
33 · median 32
Started
2012
with 4 others
Phase 2
7 of 44
1 open now
Registered
20th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 21st largest by enrollment, is one of 5 that started in 2012, is one of 7 in phase 2, and was the 20th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 15 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This multi-center, open-label study will assess the tolerability and safety of transitioning subjects with stable Pulmonary Arterial Hypertension (PAH) from continuous intravenous (IV) or subcutaneous (SC) Remodulin infusion to oral treprostinil (UT-15C sustained release (SR) tablets).

This study will consist of an in-hospital transition phase, dose optimization/evaluation phase, and follow up phase.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Arterial Hypertension
  • UT-15C SR
  • PAH
04

Who can participate

Ages eligible
15 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 15 and 80 years of age, inclusive, weigh at least 40 kg and have a diagnosis of PAH
  • Have stable disease as confirmed by recent right heart catheterization and a Baseline 6MWD of at least 250 meters
  • Have been receiving Remodulin for at least 90 days and at a stable dose for at least 30 days prior to the Baseline visit; the dose of Remodulin must be between 25-75 ng/kg/min, inclusive
  • Must be also receiving an endothelin receptor antagonist (ERA) and/or a phosphodiesterase-5 inhibitor (PDE-5i) for at least 90 days and have been at a stable dose for at least 30 days prior to Baseline

Exclusion criteria

Exclusion Criteria:

  • WHO functional class III and IV subjects will be excluded
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    UT-15C SR

    Drug: UT-15C SR

Interventions

  • Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.

06

What researchers measure

Primary outcomes

  1. Number of Participants That Were Succesfully Transitioned From Parenteral Remodulin to UT-15C.

    Successful transition was based on the number of participants that completely transitioned to oral treprostinil by the week 4 study visit and clinically maintained on oral treprostinil treatment through Week 24.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Change From Baseline in Six-minute Walk Distance at Week 24

    The purpose of the 6MWT is to evaluate exercise capacity associated with carrying out activities of daily living. Patients were instructed to walk down a corridor at a comfortable speed as far as they could manage for six minutes, resting whenever they needed. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.

    Time frame: Baseline and week 24

  2. Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 24

    The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea (difficulty in breathing) experienced during the six-minute walk test (6MWT). The Borg dyspnea score was assessed immediately following the 6MWT. Scores ranged from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).

    Time frame: Baseline and week 24

  3. Change in Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) From Baseline to Week 24

    The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning) and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.

    Time frame: Baseline and week 24

  4. Change in World Health Organization (WHO) Functional Classification From Baseline to Week 24

    Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.

    Time frame: Baseline and Week 24

  5. Change in Dyspnea-fatigue Index From Baseline to Week 24

    The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.

    Time frame: Baseline and Week 24

  6. Change From Baseline to Week 24 in Pharmacokinetic Parameters: Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), and Trough Plasma Concentration (Cmin)

    Treprostinil pharmacokinetics (PK) were evaluated on two occasions during this study, once while the subject was still receiving Remodulin and again at Week 24 when the subject was receiving a stable dose of oral treprostinil. Blood samples were scheduled to be drawn from each subject initially at time 0 and the following subsequent times: 2, 4, 5, 6, 8, 10 and 12 hours after time of study drug administration (time 0) for a total of eight samples.

    Time frame: Baseline and Week 24

  7. Change From Baseline to Week 24 in Pharmacokinetics Parameter: Peak Time to Reach Peak Plasma Concentration [Tmax (h)]

    Treprostinil pharmacokinetics (PK) were evaluated on two occasions during this study, once while the subject was still receiving Remodulin and again at Week 24 when the subject was receiving a stable dose of oral treprostinil. Blood samples were scheduled to be drawn from each subject initially at time 0 and the following subsequent times: 2, 4, 5, 6, 8, 10 and 12 hours after time of study drug administration (time 0) for a total of eight samples.

    Time frame: Baseline and Week 24

  8. Change From Baseline to Week 24 in Pharmacokinetics Parameters: Area Under the Plasma Concentration Curve (AUC) [h(ng/mL)]

    Treprostinil pharmacokinetics (PK) were evaluated on two occasions during this study, once while the subject was still receiving Remodulin and again at Week 24 when the subject was receiving a stable dose of oral treprostinil. Blood samples were scheduled to be drawn from each subject initially at time 0 and the following subsequent times: 2, 4, 5, 6, 8, 10 and 12 hours after time of study drug administration (time 0) for a total of eight samples.

    Time frame: Baseline and Week 24

  9. Change From Baseline to Week 24 in Hemodynamics Parameters: Mean Pulmonary Artery Pressure (PAPm), Mean Right Atrial Pressure (RAPm) and Mean Pulmonary Capillary Wedge Pressure (PCWPm)

    Pulmonary hypertension (PH) is an increase in pressure in the pulmonary vasculature defined as a mean pulmonary artery pressure (PAPm) greater than 25 mmHg at rest or greater than 30 mmHg with exercise, as measured by right heart catheterization. Right Atrial Pressure (RAP) is the pressure of blood in the right atrium of the heart. Pulmonary Capillary Wedge Pressure (PCWP) is used to calculated pulmonary vascular resistance and can help guide therapeutic efficacy. The PAPm, RAPm and PCWPm values and their respective changes from Baseline to Week 24 at peak exercise were measured by Swan-Ganz right heart catheterization.

    Time frame: Baseline and week 24

  10. Change From Baseline to Week 24 in Hemodynamics Parameters: Arterial Oxygen Saturation (SaO2) (%) and Mixed Venous Oxygen Saturation (SvO2) (%)

    SaO2 measured by Arterial Blood Draw and Blood Gas Analyzer and SvO2 measured via Pulmonary Artery Catheter, are both Hemodynamics Parameters collected during right heart catheterization. Mixed venous oxygen saturation (SvO2) can help to determine whether the cardiac output and oxygen delivery is high enough to meet a patient's needs

    Time frame: Baseline and Week 24

  11. Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Output (CO) (L/Min)

    Cardiac Output (CO) is the volume of blood ejected by the heart per minute, as measured by right heart catheterization. The value and change from Baseline to Week 24 at peak exercise was measured by Swan-Ganz right heart catheterization.

    Time frame: Baseline and week 24

  12. Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Index (CI) (L/Min/m^2)

    Cardiac Index (CI) relates the cardiac output (CO) from left ventricle to body surface area (BSA), thus relating heart performance to the size of the individual. The CI values and their respective changes from Baseline to Week 24 at peak exercise was measured by Swan-Ganz right heart catheterization.

    Time frame: Baseline and week 24

  13. Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)

    Pulmonary Vascular Resistance Index (PVRI) is calculated using Mean Pulmonary Arterial Pressure(PAPm), Pulmonary Capillary Wedge Pressure (PCWP) and Cardiac Index (CI ), to provide information about right ventricular overload. The PVRI values and their respective changes from Baseline to Week 24 at peak exercise was measured by Swan-Ganz right heart catheterization.

    Time frame: Baseline and week 24

  14. Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance (PVR) (mmHg*Min/L)

    pulmonary vascular resistance (PVR) is the resistance the right ventricle must overcome to pump blood into the pulmonary arteries. The change in PVR values from Baseline to Week 24 at peak exercise were measured by Swan-Ganz right heart catheterization.

    Time frame: Baseline and week 24

07

Results

Posted May 16, 2016

Participant flow

Participant flow — Overall Study
MilestoneUT-15C SR
Started33
Completed31
Not completed2
Withdrew: Adverse event1
Withdrew: Clinical worsening1

Outcome measures

PrimaryNumber of Participants That Were Succesfully Transitioned From Parenteral Remodulin to UT-15C.

Successful transition was based on the number of participants that completely transitioned to oral treprostinil by the week 4 study visit and clinically maintained on oral treprostinil treatment through Week 24.

Time frame:
Up to 24 weeks
Reported as:
Number · participants
Number of Participants That Were Succesfully Transitioned From Parenteral Remodulin to UT-15C.
participantsUT-15C SR
Number of Participants That Were Succesfully Transitioned From Parenteral Remodulin to UT-15C.31
SecondaryChange From Baseline in Six-minute Walk Distance at Week 24

The purpose of the 6MWT is to evaluate exercise capacity associated with carrying out activities of daily living. Patients were instructed to walk down a corridor at a comfortable speed as far as they could manage for six minutes, resting whenever they needed. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.

Time frame:
Baseline and week 24
Reported as:
Median · meters
Change From Baseline in Six-minute Walk Distance at Week 24
metersUT-15C SR
6MWD at Week 24467 (305 to 715)
6MWD Change from Baseline16.7 (-98.0 to 95.0)
SecondaryChange in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 24

The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea (difficulty in breathing) experienced during the six-minute walk test (6MWT). The Borg dyspnea score was assessed immediately following the 6MWT. Scores ranged from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).

Time frame:
Baseline and week 24
Reported as:
Median · units on a scale
Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 24
units on a scaleUT-15C SR
Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 240.0 (-3.5 to 3.0)
SecondaryChange in Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) From Baseline to Week 24

The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning) and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.

Time frame:
Baseline and week 24
Reported as:
Median · units on a scale
Change in Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) From Baseline to Week 24
units on a scaleUT-15C SR
Symptom-1.0 (-11 to 7)
Activity0.0 (-8 to 8)
Quality of Life0.0 (-14 to 3)
Total Camphor Score-2.0 (-25 to 17)
SecondaryChange in World Health Organization (WHO) Functional Classification From Baseline to Week 24

Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.

Time frame:
Baseline and Week 24
Reported as:
Number · participants
Change in World Health Organization (WHO) Functional Classification From Baseline to Week 24
participantsUT-15C SR
I to I3
I to II2
I to III1
II to I3
II to II21
II to III1
Missing1
SecondaryChange in Dyspnea-fatigue Index From Baseline to Week 24

The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.

Time frame:
Baseline and Week 24
Reported as:
Median · units on a scale
Change in Dyspnea-fatigue Index From Baseline to Week 24
units on a scaleUT-15C SR
Change in Dyspnea-fatigue Index From Baseline to Week 241.0 (-3 to 4)
SecondaryChange From Baseline to Week 24 in Pharmacokinetic Parameters: Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), and Trough Plasma Concentration (Cmin)

Treprostinil pharmacokinetics (PK) were evaluated on two occasions during this study, once while the subject was still receiving Remodulin and again at Week 24 when the subject was receiving a stable dose of oral treprostinil. Blood samples were scheduled to be drawn from each subject initially at time 0 and the following subsequent times: 2, 4, 5, 6, 8, 10 and 12 hours after time of study drug administration (time 0) for a total of eight samples.

Time frame:
Baseline and Week 24
Reported as:
Median · (ng/mL)
Change From Baseline to Week 24 in Pharmacokinetic Parameters: Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), and Trough Plasma Concentration (Cmin)
(ng/mL)IV Remodulin / SQ RemodulinUT-15C SR (BID)UT-15C SR (TID)
Cmax (ng/mL)8.76 (3.91 to 20.9)13 (9.41 to 20.8)12.1 (0.899 to 38.9)
Cavg (ng/mL)7.22 (2.85 to 15.4)6.89 (4.26 to 11.2)6.64 (0.345 to 22.6)
Cmin (ng/mL)5.63 (2.09 to 11.9)1.94 (1.30 to 2.97)2.45 (0.0489 to 18.6)
SecondaryChange From Baseline to Week 24 in Pharmacokinetics Parameter: Peak Time to Reach Peak Plasma Concentration [Tmax (h)]

Treprostinil pharmacokinetics (PK) were evaluated on two occasions during this study, once while the subject was still receiving Remodulin and again at Week 24 when the subject was receiving a stable dose of oral treprostinil. Blood samples were scheduled to be drawn from each subject initially at time 0 and the following subsequent times: 2, 4, 5, 6, 8, 10 and 12 hours after time of study drug administration (time 0) for a total of eight samples.

Time frame:
Baseline and Week 24
Reported as:
Mean · [Tmax (h)]
Change From Baseline to Week 24 in Pharmacokinetics Parameter: Peak Time to Reach Peak Plasma Concentration [Tmax (h)]
[Tmax (h)]IV Remodulin / SQ RemodulinUT-15C SR (BID)UT-15C SR (TID)
Change From Baseline to Week 24 in Pharmacokinetics Parameter: Peak Time to Reach Peak Plasma Concentration [Tmax (h)]4.01 (0.00 to 12.00)5.60 (3.98 to 6.0)3.92 (0.00 to 8.17)
SecondaryChange From Baseline to Week 24 in Pharmacokinetics Parameters: Area Under the Plasma Concentration Curve (AUC) [h(ng/mL)]

Treprostinil pharmacokinetics (PK) were evaluated on two occasions during this study, once while the subject was still receiving Remodulin and again at Week 24 when the subject was receiving a stable dose of oral treprostinil. Blood samples were scheduled to be drawn from each subject initially at time 0 and the following subsequent times: 2, 4, 5, 6, 8, 10 and 12 hours after time of study drug administration (time 0) for a total of eight samples.

Time frame:
Baseline and Week 24
Reported as:
Median · [h(ng/mL)]
Change From Baseline to Week 24 in Pharmacokinetics Parameters: Area Under the Plasma Concentration Curve (AUC) [h(ng/mL)]
[h(ng/mL)]IV Remodulin / SQ RemodulinUT-15C SR (BID)UT-15C SR (TID)
Change From Baseline to Week 24 in Pharmacokinetics Parameters: Area Under the Plasma Concentration Curve (AUC) [h(ng/mL)]86.3 (34.2 to 185)82.5 (49.7 to 134)81.8 (7.18 to 277)
SecondaryChange From Baseline to Week 24 in Hemodynamics Parameters: Mean Pulmonary Artery Pressure (PAPm), Mean Right Atrial Pressure (RAPm) and Mean Pulmonary Capillary Wedge Pressure (PCWPm)

Pulmonary hypertension (PH) is an increase in pressure in the pulmonary vasculature defined as a mean pulmonary artery pressure (PAPm) greater than 25 mmHg at rest or greater than 30 mmHg with exercise, as measured by right heart catheterization. Right Atrial Pressure (RAP) is the pressure of blood in the right atrium of the heart. Pulmonary Capillary Wedge Pressure (PCWP) is used to calculated pulmonary vascular resistance and can help guide therapeutic efficacy. The PAPm, RAPm and PCWPm values and their respective changes from Baseline to Week 24 at peak exercise were measured by Swan-Ganz right heart catheterization.

Time frame:
Baseline and week 24
Reported as:
Mean · mmHg
Change From Baseline to Week 24 in Hemodynamics Parameters: Mean Pulmonary Artery Pressure (PAPm), Mean Right Atrial Pressure (RAPm) and Mean Pulmonary Capillary Wedge Pressure (PCWPm)
mmHgUT-15C SR
PAPm (mmHg)2.2 ± 8.6
RAPm (mmHg)0.5 ± 3.7
PCWPm (mmHg)0.6 ± 4.6
SecondaryChange From Baseline to Week 24 in Hemodynamics Parameters: Arterial Oxygen Saturation (SaO2) (%) and Mixed Venous Oxygen Saturation (SvO2) (%)

SaO2 measured by Arterial Blood Draw and Blood Gas Analyzer and SvO2 measured via Pulmonary Artery Catheter, are both Hemodynamics Parameters collected during right heart catheterization. Mixed venous oxygen saturation (SvO2) can help to determine whether the cardiac output and oxygen delivery is high enough to meet a patient's needs

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent of Oxygen saturation
Change From Baseline to Week 24 in Hemodynamics Parameters: Arterial Oxygen Saturation (SaO2) (%) and Mixed Venous Oxygen Saturation (SvO2) (%)
Percent of Oxygen saturationUT-15C SR
SaO2 (%)-0.1 ± 3.4
SvO2 (%)-3.2 ± 5.2
SecondaryChange From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Output (CO) (L/Min)

Cardiac Output (CO) is the volume of blood ejected by the heart per minute, as measured by right heart catheterization. The value and change from Baseline to Week 24 at peak exercise was measured by Swan-Ganz right heart catheterization.

Time frame:
Baseline and week 24
Reported as:
Mean · L/min
Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Output (CO) (L/Min)
L/minUT-15C SR
Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Output (CO) (L/Min)-0.3 ± 1.3
SecondaryChange From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Index (CI) (L/Min/m^2)

Cardiac Index (CI) relates the cardiac output (CO) from left ventricle to body surface area (BSA), thus relating heart performance to the size of the individual. The CI values and their respective changes from Baseline to Week 24 at peak exercise was measured by Swan-Ganz right heart catheterization.

Time frame:
Baseline and week 24
Reported as:
Mean · L/min/m^2
Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Index (CI) (L/Min/m^2)
L/min/m^2UT-15C SR
Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Index (CI) (L/Min/m^2)-0.1 ± 0.7
SecondaryChange From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)

Pulmonary Vascular Resistance Index (PVRI) is calculated using Mean Pulmonary Arterial Pressure(PAPm), Pulmonary Capillary Wedge Pressure (PCWP) and Cardiac Index (CI ), to provide information about right ventricular overload. The PVRI values and their respective changes from Baseline to Week 24 at peak exercise was measured by Swan-Ganz right heart catheterization.

Time frame:
Baseline and week 24
Reported as:
Mean · mmHg*min*m^2/L
Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)
mmHg*min*m^2/LUT-15C SR
Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)1.6 ± 4.8
SecondaryChange From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance (PVR) (mmHg*Min/L)

pulmonary vascular resistance (PVR) is the resistance the right ventricle must overcome to pump blood into the pulmonary arteries. The change in PVR values from Baseline to Week 24 at peak exercise were measured by Swan-Ganz right heart catheterization.

Time frame:
Baseline and week 24
Reported as:
Mean · mmHg*min/L
Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance (PVR) (mmHg*Min/L)
mmHg*min/LUT-15C SR
Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance (PVR) (mmHg*Min/L)0.8 ± 2.4

Adverse events

Collected over Adverse events were recorded throughout the 24-week study, including the screening and follow-up phase, as well as 30 days post end of study visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UT-15C SR—9/33 (27.3%)32/33 (97%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventUT-15C SR
DiarrhoeaGastrointestinal disorders2/33
NauseaGastrointestinal disorders2/33
VertigoNervous system disorders2/33
Abdominal DistensionGastrointestinal disorders1/33
AnemiaBlood and lymphatic system disorders1/33
AscitesHepatobiliary disorders1/33
Atrial FlutterCardiac disorders1/33
DyspneaRespiratory, thoracic and mediastinal disorders1/33
Gastric UlcerGastrointestinal disorders1/33
Gastroenteritis ViralInfections and infestations1/33
Most frequent other events
Showing 10 of 52
Most frequent other events
EventUT-15C SR
HeadacheNervous system disorders28/33
FlushingVascular disorders23/33
NauseaGastrointestinal disorders22/33
DiarrhoeaGastrointestinal disorders20/33
FatigueGeneral disorders16/33
VomitingGastrointestinal disorders14/33
DyspepsiaGastrointestinal disorders13/33
Upper Resipiratory Tract InfectionRespiratory, thoracic and mediastinal disorders10/33
DyspneaRespiratory, thoracic and mediastinal disorders9/33
DizzinessNervous system disorders8/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)UT-15C SR
Median50.0 (18 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)UT-15C SR
Female25
Male8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)UT-15C SR
American Indian or Alaska Native2
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American1
White28
More than one race0
Unknown or Not Reported0
08

Study locations

6 sites
  • Arizona Pulmonary Specialists
    Phoenix, Arizona 85013, United States
  • University of Arizona Clinical and Translational Science (CATS) Research Center
    Tucson, Arizona 85724, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • The Ohio State University
    Columbus, Ohio 43221, United States
  • University of Pittsburgh Medical Center (UPMC)
    Pittsburgh, Pennsylvania 15213, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jul 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2012
First posted
May 1, 2012
Start
Apr 2012
Primary completionActual
Jul 2014
CompletionActual
Dec 2014
Results first posted
May 16, 2016
Last update
May 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01588405
Responsible party
Sponsor
First posted
May 1, 2012
Start date
Apr 2012
Primary completion
Jul 2014
Completion
Dec 2014
Results posted
May 16, 2016
Last update
May 16, 2016

Study contacts

Cynthia Madden, MD, MPH
study chair · Senior Clinical Research Physician

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion